Search research articles
Contact Us
Filters
Showing results (91-100 of 98) with videos related to
Page
of 10
Sort By:
You have reached the last page of results.
This site can display upto 98 results.
Proceedings of the National Academy of Sciences of the United States of America
|
October 31, 2008
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
Sven Rottenberg, Janneke E Jaspers, Ariena Kersbergen, et al.
Cancer Research
|
August 24, 2016
The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models
Lenka Oplustil O'Connor, Stuart L Rulten, Aaron N Cranston, et al.
Molecular Cancer Therapeutics
|
May 12, 2012
Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3K
Joanne M Munck, Michael A Batey, Yan Zhao, et al.
Bioorganic & Medicinal Chemistry Letters
|
April 20, 2005
Phthalazinones. Part 1: The design and synthesis of a novel series of potent inhibitors of poly(ADP-ribose)polymerase
Vincent M Loh, Xiao-ling Cockcroft, Krystyna J Dillon, et al.
Journal of Medicinal Chemistry
|
September 20, 2008
4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1
Keith A Menear, Claire Adcock, Robert Boulter, et al.
Journal of Medicinal Chemistry
|
March 21, 2007
Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependent protein kinase inhibition, and identification of the first potent and selective inhibitor of the ataxia telangiectasia mutated kinase
Jonathan J Hollick, Laurent J M Rigoreau, Celine Cano-Soumillac, et al.
Journal of Medicinal Chemistry
|
June 20, 1997
Structure-activity relationships of N-hydroxyurea 5-lipoxygenase inhibitors
A O Stewart, P A Bhatia, J G Martin, et al.
Nature Communications
|
June 18, 2021
Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance
Diana Zatreanu, Helen M R Robinson, Omar Alkhatib, et al.
Page
of 10
Search research articles
Search
Showing results (91-100 of 98) with videos related to
Sort By:
Page
of 10
You have reached the last page of results.
This site can display upto 98 results.
Proceedings of the National Academy of Sciences of the United States of America
|
October 31, 2008
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
Sven Rottenberg, Janneke E Jaspers, Ariena Kersbergen, et al.
Cancer Research
|
August 24, 2016
The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models
Lenka Oplustil O'Connor, Stuart L Rulten, Aaron N Cranston, et al.
Molecular Cancer Therapeutics
|
May 12, 2012
Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3K
Joanne M Munck, Michael A Batey, Yan Zhao, et al.
Bioorganic & Medicinal Chemistry Letters
|
April 20, 2005
Phthalazinones. Part 1: The design and synthesis of a novel series of potent inhibitors of poly(ADP-ribose)polymerase
Vincent M Loh, Xiao-ling Cockcroft, Krystyna J Dillon, et al.
Journal of Medicinal Chemistry
|
September 20, 2008
4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1
Keith A Menear, Claire Adcock, Robert Boulter, et al.
Journal of Medicinal Chemistry
|
March 21, 2007
Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependent protein kinase inhibition, and identification of the first potent and selective inhibitor of the ataxia telangiectasia mutated kinase
Jonathan J Hollick, Laurent J M Rigoreau, Celine Cano-Soumillac, et al.
Journal of Medicinal Chemistry
|
June 20, 1997
Structure-activity relationships of N-hydroxyurea 5-lipoxygenase inhibitors
A O Stewart, P A Bhatia, J G Martin, et al.
Nature Communications
|
June 18, 2021
Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance
Diana Zatreanu, Helen M R Robinson, Omar Alkhatib, et al.
Page
of 10